Cargando…

Nitazoxanide: A first-in-class broad-spectrum antiviral agent

Originally developed and commercialized as an antiprotozoal agent, nitazoxanide was later identified as a first-in-class broad-spectrum antiviral drug and has been repurposed for the treatment of influenza. A Phase 2b/3 clinical trial recently published in The Lancet Infectious Diseases found that o...

Descripción completa

Detalles Bibliográficos
Autor principal: Rossignol, Jean-François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author. Published by Elsevier B.V. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113776/
https://www.ncbi.nlm.nih.gov/pubmed/25108173
http://dx.doi.org/10.1016/j.antiviral.2014.07.014